New imaging technique could predict success of CAR T-Cell therapy in lymphoma patients

NCT ID NCT05404048

Ongoing Knowledge-focused Sponsor: University Medical Center Groningen Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This pilot study tests a new PET imaging method using a tracer called 89Zr-atezolizumab to see if it can predict how well patients with large B-cell lymphoma respond to CAR T-cell therapy. The study involves 20 participants and aims to determine if this imaging can also tell the difference between active lymphoma and inflammation caused by treatment. The goal is to improve treatment decisions and outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 89Zr-atezolizumab (a radioactive tracer for PET imaging)
What this could lead to: If successful, this imaging method could help doctors predict which patients will respond to CAR T-cell therapy and avoid unnecessary treatments.
What could go wrong: This is a small pilot study with only 20 participants, so results may not apply to everyone. The imaging technique is experimental and may not reliably distinguish lymphoma from inflammation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LARGE B-CELL LYMPHOMA

Contacts and locations

Locations

University Medical Center Groningen

Groningen, 9713GZ, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.